Pharmacotherapy for artemisinin-resistant malaria
Expert Opin Pharmacother. 2021 Jul 27. doi: 10.1080/14656566.2021.1959913. Online ahead of print.ABSTRACTINTRODUCTION: Malaria, the most devastating parasitic disease, is currently treated with artemisinin-based combination therapies (ACTs). Unfortunately, some ACTs are unable to rapidly clear Plasmodium falciparum parasites from the blood stream and are failing to cure malaria patients; a problem, so far, largely confined to Southeast Asia. There is a fear of resistant Plasmodium falciparum emerging in other parts of the world including Sub-Sahara Africa. Strategies for alternative treatments, ideally non-artemisinin base...
Source: Expert Opinion on Pharmacotherapy - July 27, 2021 Category: Drugs & Pharmacology Authors: Erik Koehne Ayola Akim Adegnika Jana Held Andrea Kreidenweiss Source Type: research

Development of the PARP inhibitor talazoparib for the treatment of advanced < em > BRCA1 < /em > and < em > BRCA2 < /em > mutated breast cancer
Expert Opin Pharmacother. 2021 Jul 26:1-13. doi: 10.1080/14656566.2021.1952181. Online ahead of print.ABSTRACTINTRODUCTION: BRCA1 and BRCA2 (BRCA1/2) mutation breast cancers constitute an uncommon, but unique group of breast cancers that present at a younger age, and are underscored by genomic instability and accumulation of DNA damage. Talazoparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor that exploits impaired DNA damage response mechanisms in this population of patients and results in significant efficacy. Based on the results of the EMBRACA trial, talazoparib was approved for the treatment of patients wi...
Source: Expert Opinion on Pharmacotherapy - July 26, 2021 Category: Drugs & Pharmacology Authors: Evthokia A Hobbs Jennifer K Litton Timothy A Yap Source Type: research

The role of amikacin in the treatment of nontuberculous mycobacterial disease
Expert Opin Pharmacother. 2021 Jul 22:1-14. doi: 10.1080/14656566.2021.1953472. Online ahead of print.ABSTRACTIntroduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment.Areas covered: The authors performed a literature search for original research on amikacin in NTM disease, including its mechanism of action, emergence of resistance, pre-clinical and clinical investigations.Expert opinion: Amikacin shows moderate in vitro activity against the clinically most relevant NTM ...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Jelmer Raaijmakers Jodie Schildkraut Wouter Hoefsloot Jakko van Ingen Source Type: research

Bexagliflozin for type 2 Diabetes: an overview of the data
Expert Opin Pharmacother. 2021 Jul 22. doi: 10.1080/14656566.2021.1959915. Online ahead of print.ABSTRACTINTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a relatively novel glucose-lowering drugs (GLDs) which additionally promote weight loss and blood pressure reduction amongst other beneficial effects.AREAS COVERED: This review reflects on the extra-glycaemic effects of SGLT2 inhibitors and their impact on important clinical endpoints, and provides an overview of data relating to a newer member of the SGLT2 inhibitor class, bexagliflozin.EXPERT OPINION: SGLT2 inhibitors, while consolidating glycaemic co...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Omar Azzam Revathy Carnagarin Leslie Marisol Lugo-Gavidia Janis Nolde Vance B Matthews Markus P Schlaich Source Type: research

The role of amikacin in the treatment of nontuberculous mycobacterial disease
Expert Opin Pharmacother. 2021 Jul 22:1-14. doi: 10.1080/14656566.2021.1953472. Online ahead of print.ABSTRACTIntroduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment.Areas covered: The authors performed a literature search for original research on amikacin in NTM disease, including its mechanism of action, emergence of resistance, pre-clinical and clinical investigations.Expert opinion: Amikacin shows moderate in vitro activity against the clinically most relevant NTM ...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Jelmer Raaijmakers Jodie Schildkraut Wouter Hoefsloot Jakko van Ingen Source Type: research

Bexagliflozin for type 2 Diabetes: an overview of the data
Expert Opin Pharmacother. 2021 Jul 22. doi: 10.1080/14656566.2021.1959915. Online ahead of print.ABSTRACTINTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a relatively novel glucose-lowering drugs (GLDs) which additionally promote weight loss and blood pressure reduction amongst other beneficial effects.AREAS COVERED: This review reflects on the extra-glycaemic effects of SGLT2 inhibitors and their impact on important clinical endpoints, and provides an overview of data relating to a newer member of the SGLT2 inhibitor class, bexagliflozin.EXPERT OPINION: SGLT2 inhibitors, while consolidating glycaemic co...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Omar Azzam Revathy Carnagarin Leslie Marisol Lugo-Gavidia Janis Nolde Vance B Matthews Markus P Schlaich Source Type: research

The role of amikacin in the treatment of nontuberculous mycobacterial disease
Expert Opin Pharmacother. 2021 Jul 22:1-14. doi: 10.1080/14656566.2021.1953472. Online ahead of print.ABSTRACTIntroduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment.Areas covered: The authors performed a literature search for original research on amikacin in NTM disease, including its mechanism of action, emergence of resistance, pre-clinical and clinical investigations.Expert opinion: Amikacin shows moderate in vitro activity against the clinically most relevant NTM ...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Jelmer Raaijmakers Jodie Schildkraut Wouter Hoefsloot Jakko van Ingen Source Type: research

Bexagliflozin for type 2 Diabetes: an overview of the data
Expert Opin Pharmacother. 2021 Jul 22. doi: 10.1080/14656566.2021.1959915. Online ahead of print.ABSTRACTINTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a relatively novel glucose-lowering drugs (GLDs) which additionally promote weight loss and blood pressure reduction amongst other beneficial effects.AREAS COVERED: This review reflects on the extra-glycaemic effects of SGLT2 inhibitors and their impact on important clinical endpoints, and provides an overview of data relating to a newer member of the SGLT2 inhibitor class, bexagliflozin.EXPERT OPINION: SGLT2 inhibitors, while consolidating glycaemic co...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Omar Azzam Revathy Carnagarin Leslie Marisol Lugo-Gavidia Janis Nolde Vance B Matthews Markus P Schlaich Source Type: research

The role of amikacin in the treatment of nontuberculous mycobacterial disease
Expert Opin Pharmacother. 2021 Jul 22:1-14. doi: 10.1080/14656566.2021.1953472. Online ahead of print.ABSTRACTIntroduction: Guidelines recommend the use of amikacin in the treatment of nontuberculous mycobacterial (NTM) disease. The authors have evaluated the evidence for the position of amikacin in NTM disease treatment.Areas covered: The authors performed a literature search for original research on amikacin in NTM disease, including its mechanism of action, emergence of resistance, pre-clinical and clinical investigations.Expert opinion: Amikacin shows moderate in vitro activity against the clinically most relevant NTM ...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Jelmer Raaijmakers Jodie Schildkraut Wouter Hoefsloot Jakko van Ingen Source Type: research

Bexagliflozin for type 2 Diabetes: an overview of the data
Expert Opin Pharmacother. 2021 Jul 22. doi: 10.1080/14656566.2021.1959915. Online ahead of print.ABSTRACTINTRODUCTION: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a relatively novel glucose-lowering drugs (GLDs) which additionally promote weight loss and blood pressure reduction amongst other beneficial effects.AREAS COVERED: This review reflects on the extra-glycaemic effects of SGLT2 inhibitors and their impact on important clinical endpoints, and provides an overview of data relating to a newer member of the SGLT2 inhibitor class, bexagliflozin.EXPERT OPINION: SGLT2 inhibitors, while consolidating glycaemic co...
Source: Expert Opinion on Pharmacotherapy - July 22, 2021 Category: Drugs & Pharmacology Authors: Omar Azzam Revathy Carnagarin Leslie Marisol Lugo-Gavidia Janis Nolde Vance B Matthews Markus P Schlaich Source Type: research

Dapagliflozin for the treatment of Type 2 Diabetes Mellitus - An Update
Expert Opin Pharmacother. 2021 Jul 20. doi: 10.1080/14656566.2021.1953471. Online ahead of print.ABSTRACTINTRODUCTION: Diabetes is a global health concern with a prevalence of 463 million people. Importantly, despite the availability of numerous antidiabetic medications, type 2 diabetes mellitus (T2DM) is still associated with significant morbidity and mortality worldwide. One particular drug of interest is dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is commonly used in the treatment of Type 2 Diabetes Mellitus (T2DM).AREAS COVERED: This review outlines the current use and pharmacology of dapagli...
Source: Expert Opinion on Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Martha K Nicholson Randa Ghazal Asswad John Ph Wilding Source Type: research

The treatment of advanced lung adenocarcinoma with activating EGFR mutations
Expert Opin Pharmacother. 2021 Jul 22:1-8. doi: 10.1080/14656566.2021.1957096. Online ahead of print.ABSTRACTINTRODUCTION: Lung adenocarcinomas account for approximately 40-50% of all NSCLC (Non-Small Cell Lung Cancer) cases. In addition, lung adenocarcinomas can harbor several different genetic mutations, EGFR (Epidermal Growth Factor Receptor) being the most frequent one, accounting for approximately 5-15% of all the mutations in western patients and for approximately 40-55% in Asian patients; on the other hand, EGFR mutations are uncommon in squamous histology. Approximately 90% of EGFR mutations are represented by exon...
Source: Expert Opinion on Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Danilo Rocco Luigi Della Gravara Ciro Battiloro Paolo Maione Cesare Gridelli Source Type: research

Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art
Expert Opin Pharmacother. 2021 Jul 22:1-6. doi: 10.1080/14656566.2021.1957097. Online ahead of print.ABSTRACTIntroduction: Cryptosporidiosis has emerged as a major cause of diarrheal disease worldwide. It has especially serious health consequences for young, malnourished children living in endemic areas and for individuals with highly impaired T-cell function, such as HIV-positive individuals with low CD4 counts or immunosuppressed solid-organ transplant recipients.Areas covered: A selective literature search using PubMed was performed to review the available therapeutics to treat cryptosporidiosis, as well as related adva...
Source: Expert Opinion on Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Anne Schneider Sebastian Wendt Christoph L übbert Henning Trawinski Source Type: research

Dapagliflozin for the treatment of Type 2 Diabetes Mellitus - An Update
Expert Opin Pharmacother. 2021 Jul 20. doi: 10.1080/14656566.2021.1953471. Online ahead of print.ABSTRACTINTRODUCTION: Diabetes is a global health concern with a prevalence of 463 million people. Importantly, despite the availability of numerous antidiabetic medications, type 2 diabetes mellitus (T2DM) is still associated with significant morbidity and mortality worldwide. One particular drug of interest is dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is commonly used in the treatment of Type 2 Diabetes Mellitus (T2DM).AREAS COVERED: This review outlines the current use and pharmacology of dapagli...
Source: Expert Opinion on Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Martha K Nicholson Randa Ghazal Asswad John Ph Wilding Source Type: research

The treatment of advanced lung adenocarcinoma with activating EGFR mutations
Expert Opin Pharmacother. 2021 Jul 20. doi: 10.1080/14656566.2021.1957096. Online ahead of print.ABSTRACTIntroduction: Lung adenocarcinomas account for approximately 40-50% of all NSCLC (Non-Small Cell Lung Cancer) cases. In addition, lung adenocarcinomas can harbor several different genetic mutations, EGFR (Epidermal Growth Factor Receptor) being the most frequent one, accounting for approximately 5-15% of all the mutations in western patients and for approximately 40-55% in Asian patients; on the other hand, EGFR mutations are uncommon in squamous histology. Approximately 90% of EGFR mutations are represented by exon 19 ...
Source: Expert Opinion on Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Danilo Rocco Luigi Della Gravara Ciro Battiloro Paolo Maione Cesare Gridelli Source Type: research

Current pharmacotherapy of cryptosporidiosis: An update of the state-of-the-art
Expert Opin Pharmacother. 2021 Jul 20. doi: 10.1080/14656566.2021.1957097. Online ahead of print.ABSTRACTCryptosporidiosis has emerged as a major cause of diarrheal disease worldwide. It has especially serious health consequences for young, malnourished children living in endemic areas and for individuals with highly impaired T-cell function, such as HIV-positive individuals with low CD4 counts or immunosuppressed solid-organ transplant recipients.Areas covered:A selective literature search using PubMed was performed to review the available therapeutics to treat cryptosporidiosis, as well as related advances in drug develo...
Source: Expert Opinion on Pharmacotherapy - July 20, 2021 Category: Drugs & Pharmacology Authors: Anne Schneider Sebastian Wendt Christoph L übbert Henning Trawinski Source Type: research

Advances in Pharmacotherapy for Neuroblastoma
Expert Opin Pharmacother. 2021 Jul 13. doi: 10.1080/14656566.2021.1953470. Online ahead of print.ABSTRACTNeuroblastoma is the most prevalent cancer type diagnosed within the first year after birth and accounts for 15% of deaths from pediatric cancer. Despite the improvements in survival rates of patients with neuroblastoma, the incidence of the disease has increased over the last decade. Neuroblastoma tumor cells harbor a vast range of variable and heterogeneous histochemical and genetic alterations which calls for the need to administer individualized and targeted therapies to induce tumor regression in each patient.Areas...
Source: Expert Opinion on Pharmacotherapy - July 13, 2021 Category: Drugs & Pharmacology Authors: Parmida Sadat Pezeshki Aysan Moeinafshar Faezeh Ghaemdoust Sepideh Razi Mahsa Keshavarz-Fathi Nima Rezaei Source Type: research

An Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer
Expert Opin Pharmacother. 2021 Jul 12. doi: 10.1080/14656566.2021.1952983. Online ahead of print.ABSTRACTINTRODUCTION: : Men with prostate cancer undergoing castration will eventually progress. In addition to androgen receptor pathway inhibitors (like abiraterone and enzalutamide) or chemotherapy (like docetaxel), exists olaparib, a relatively new drug that interferes with the base excision repair (BER) pathway mainly due to selective inhibition of Poly ADP-ribose polymerase (PARP) 1 and 2.AREAS COVERED: : Herein, the authors evaluate the basic characteristics of olaparib, including its pharmacokinetics, mechanism of actio...
Source: Expert Opinion on Pharmacotherapy - July 12, 2021 Category: Drugs & Pharmacology Authors: Panagiotis Mourmouris Athanasios Papatsoris Athanasios Dellis Iraklis Mitsogiannis Mohamed Abou Chakra Mohamad Moussa Source Type: research

Key Considerations in the Pharmacological Management of Treatment-Resistant Depression
Expert Opin Pharmacother. 2021 Jul 12. doi: 10.1080/14656566.2021.1951225. Online ahead of print.ABSTRACTIntroduction: Treatment-resistant depression (TRD) is a complex, multifactorial, and biologically heterogeneous disorder with debilitating outcomes. Understanding individual reasons why patients do not respond to treatment is necessary for improving clinical recommendations regarding medication regimens, augmentation strategies, and alternative treatments.Areas covered in this review: This manuscript reviews evidence-based treatment strategies for the clinical management of TRD. Current developments in the field and pot...
Source: Expert Opinion on Pharmacotherapy - July 12, 2021 Category: Drugs & Pharmacology Authors: Mani Yavi Ioline D Henter Lawrence T Park Carlos Zarate Source Type: research

Evolving Therapeutic Strategies for Advanced Hepatocellular Carcinoma
Expert Opin Pharmacother. 2021 Jul 12. doi: 10.1080/14656566.2021.1953473. Online ahead of print.ABSTRACTINTRODUCTION: While sorafenib dominated the therapeutic arena in advanced hepatocellular carcinoma (HCC) for almost a decade, newer agents and combinations have been changing the therapeutic landscape in the last years.AREAS COVERED: : The authors outline the etiopathogenesis and evaluate the diagnostics in HCC, followed by a comprehensive review of the currently approved and experimental treatment approaches, with a focus on various systemic agents and combinations of agents. The manuscript was subdivided into relevant...
Source: Expert Opinion on Pharmacotherapy - July 12, 2021 Category: Drugs & Pharmacology Authors: Ammar Qureshi Miguel Michel Jaren Lerner Constantin A Dasanu Source Type: research

How urgent is the need for new antifungals?
Expert Opin Pharmacother. 2021 Jul 7:1-14. doi: 10.1080/14656566.2021.1935868. Online ahead of print.ABSTRACTIntroduction: Invasive fungal infection carries a high morbidity, mortality and economic cost. In recent times, a rising incidence of fungal infection and antifungal resistance is occurring which has prompted the development of novel antifungal agents.Areas covered:In this perspective, the authors describe the current status of registered antifungals and their limitations in the treatment of invasive fungal infection. They also go on to describe the new antifungal agents that are in the clinical stage of development...
Source: Expert Opinion on Pharmacotherapy - July 7, 2021 Category: Drugs & Pharmacology Authors: Adam G Stewart David L Paterson Source Type: research

An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer
Expert Opin Pharmacother. 2021 Jul 6. doi: 10.1080/14656566.2021.1948014. Online ahead of print.ABSTRACTIntroduction: Alectinib is a second-generation inhibitor of anaplastic lymphoma kinase (ALK) and RET. Phase III clinical trials have established its superiority to crizotinib in the first-line ALK inhibitor-naïve setting. Studies also support its use over chemotherapy in the post-crizotinib setting. It is currently one of several FDA- and EMA-approved ALK inhibitors, and it is listed as a preferred initial therapy for treatment-naïve ALK-positive non-small cell lung cancer (NSCLC).Areas covered: Herein, the aut...
Source: Expert Opinion on Pharmacotherapy - July 6, 2021 Category: Drugs & Pharmacology Authors: Shiruyeh Schokrpur Van Hilburn Nicholas Giustini Lyudmila Bazhenova Source Type: research

An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Beh çet's syndrome
Expert Opin Pharmacother. 2021 Jul 5:1-5. doi: 10.1080/14656566.2021.1939307. Online ahead of print.ABSTRACTINTRODUCTION: Behçet's syndrome is a chronic, multi-system, variable vasculitis of unknown etiology that can result in significant morbidity and mortality. Mucocutaneous lesions such as oral ulcers and genital ulcers are common manifestations that can affect the quality of life of patients significantly. Treatment for mucocutaneous lesions in Behçet's syndrome continues to be critical, and an unmet need remains a significant issue.AREAS COVERED: This review evaluates the mechanism of action of apremilas...
Source: Expert Opinion on Pharmacotherapy - July 5, 2021 Category: Drugs & Pharmacology Authors: Ay şe Özdede G ülen Hatemi Source Type: research

Current long-acting muscarinic antagonists for the treatment of asthma
Expert Opin Pharmacother. 2021 Jul 3. doi: 10.1080/14656566.2021.1952182. Online ahead of print.ABSTRACTINTRODUCTION: The role of long-acting muscarinic antagonists (LAMAs) is well established in uncontrolled asthma, but not in milder stages.AREAS COVERED: This review examines the main randomized controlled trials (RCTs) that have investigated LAMAs administered as monotherapy or in combination to asthmatic patients, according to the different phenotypes. It offers an overview of the role of LAMAs or their fixed dose combinations (FDCs) in the treatment across all the different stages of asthma.EXPERT OPINION: Tiotropium i...
Source: Expert Opinion on Pharmacotherapy - July 5, 2021 Category: Drugs & Pharmacology Authors: Josuel Ora Luigino Calzetta Beatrice Ludovica Ritondo Maria Gabriella Matera Paola Rogliani Source Type: research

Can We Rely on Synthetic Pharmacotherapy for the Treatment of Glioblastoma?
This study reviews synthetic pharmacotherapies that are currently under investigation in phase I - III clinical trials. The authors of this study highlight the mechanisms of action of the synthetic pharmacotherapy agents under investigation, outline the available evidence for their utility based on the literature, and summarize the current landscape.Expert opinion: Although warranting further investigation, the studies generally highlighted here have not shown remarkable changes in clinical benefits beyond what has already been established with radiochemotherapy. As we develop more synthetics, we will likely need to combin...
Source: Expert Opinion on Pharmacotherapy - July 5, 2021 Category: Drugs & Pharmacology Authors: Chibueze D Nwagwu David C Adamson Source Type: research

An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Beh çet's syndrome
Expert Opin Pharmacother. 2021 Jul 5:1-5. doi: 10.1080/14656566.2021.1939307. Online ahead of print.ABSTRACTINTRODUCTION: Behçet's syndrome is a chronic, multi-system, variable vasculitis of unknown etiology that can result in significant morbidity and mortality. Mucocutaneous lesions such as oral ulcers and genital ulcers are common manifestations that can affect the quality of life of patients significantly. Treatment for mucocutaneous lesions in Behçet's syndrome continues to be critical, and an unmet need remains a significant issue.AREAS COVERED: This review evaluates the mechanism of action of apremilas...
Source: Expert Opinion on Pharmacotherapy - July 5, 2021 Category: Drugs & Pharmacology Authors: Ay şe Özdede G ülen Hatemi Source Type: research

Current long-acting muscarinic antagonists for the treatment of asthma
Expert Opin Pharmacother. 2021 Jul 3. doi: 10.1080/14656566.2021.1952182. Online ahead of print.ABSTRACTINTRODUCTION: The role of long-acting muscarinic antagonists (LAMAs) is well established in uncontrolled asthma, but not in milder stages.AREAS COVERED: This review examines the main randomized controlled trials (RCTs) that have investigated LAMAs administered as monotherapy or in combination to asthmatic patients, according to the different phenotypes. It offers an overview of the role of LAMAs or their fixed dose combinations (FDCs) in the treatment across all the different stages of asthma.EXPERT OPINION: Tiotropium i...
Source: Expert Opinion on Pharmacotherapy - July 5, 2021 Category: Drugs & Pharmacology Authors: Josuel Ora Luigino Calzetta Beatrice Ludovica Ritondo Maria Gabriella Matera Paola Rogliani Source Type: research

Can We Rely on Synthetic Pharmacotherapy for the Treatment of Glioblastoma?
This study reviews synthetic pharmacotherapies that are currently under investigation in phase I - III clinical trials. The authors of this study highlight the mechanisms of action of the synthetic pharmacotherapy agents under investigation, outline the available evidence for their utility based on the literature, and summarize the current landscape.Expert opinion: Although warranting further investigation, the studies generally highlighted here have not shown remarkable changes in clinical benefits beyond what has already been established with radiochemotherapy. As we develop more synthetics, we will likely need to combin...
Source: Expert Opinion on Pharmacotherapy - July 5, 2021 Category: Drugs & Pharmacology Authors: Chibueze D Nwagwu David C Adamson Source Type: research

Can cannabinoids still play a role as pain medications?
Expert Opin Pharmacother. 2021 Jun 30:1-3. doi: 10.1080/14656566.2021.1946515. Online ahead of print.NO ABSTRACTPMID:34187250 | DOI:10.1080/14656566.2021.1946515 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Thomas P Pittelkow Neha Pawar Jonathan M Hagedorn Source Type: research

Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer
Expert Opin Pharmacother. 2021 Jun 30:1-9. doi: 10.1080/14656566.2021.1948012. Online ahead of print.ABSTRACTIntroduction:Androgen deprivation therapy (ADT) is currently the backbone treatment of metastatic prostate cancer and is also used in combination with external beam radiotherapy (EBRT). Castration may be achieved either by bilateral orchiectomy or by administration of LHRH agonists or GnRH antagonists.Areas covered: In this article, the authors assess the current and emerging role of GnRH antagonists for the treatment of prostate cancer focusing on oncological results and safety (i.e. cardiovascular risk). In additi...
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Mohamad Moussa Athanasios Papatsoris Athanasios Dellis Mohamed Abou Chakra Charalampos Fragkoulis Source Type: research

How to reduce medication errors in patients over the age of 65?
Expert Opin Pharmacother. 2021 Jun 30:1-5. doi: 10.1080/14656566.2021.1947241. Online ahead of print.NO ABSTRACTPMID:34187264 | DOI:10.1080/14656566.2021.1947241 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Jos é Joaquín Mira Source Type: research

Advances in pharmacotherapy for head and neck cancer
Expert Opin Pharmacother. 2021 Jun 30:1-12. doi: 10.1080/14656566.2021.1948011. Online ahead of print.ABSTRACTIntroduction: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide and is a leading cause for cancer-related mortality. This review attempts to give a comprehensive summary of the recent developments in pharmacotherapeutic options for locally advanced/metastatic HNSCC.Areas covered: In this review, the authors conducted a systematic literature search for published articles on HNSCC in the PubMed database using the keywords 'head and neck squamous cell carcinoma or HNSCC,' 'targe...
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Shikhar Kumar Vanita Noronha Vijay Patil Amit Joshi Nandini Menon Kumar Prabhash Source Type: research

When is it appropriate to treat children with social anxiety, pharmacologically?
Expert Opin Pharmacother. 2021 Jun 30:1-4. doi: 10.1080/14656566.2021.1948015. Online ahead of print.NO ABSTRACTPMID:34187275 | DOI:10.1080/14656566.2021.1948015 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Avigal Snir Danielle M Moskow Stefan G Hofmann Source Type: research

Can cannabinoids still play a role as pain medications?
Expert Opin Pharmacother. 2021 Jun 30:1-3. doi: 10.1080/14656566.2021.1946515. Online ahead of print.NO ABSTRACTPMID:34187250 | DOI:10.1080/14656566.2021.1946515 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Thomas P Pittelkow Neha Pawar Jonathan M Hagedorn Source Type: research

Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer
Expert Opin Pharmacother. 2021 Jun 30:1-9. doi: 10.1080/14656566.2021.1948012. Online ahead of print.ABSTRACTIntroduction:Androgen deprivation therapy (ADT) is currently the backbone treatment of metastatic prostate cancer and is also used in combination with external beam radiotherapy (EBRT). Castration may be achieved either by bilateral orchiectomy or by administration of LHRH agonists or GnRH antagonists.Areas covered: In this article, the authors assess the current and emerging role of GnRH antagonists for the treatment of prostate cancer focusing on oncological results and safety (i.e. cardiovascular risk). In additi...
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Mohamad Moussa Athanasios Papatsoris Athanasios Dellis Mohamed Abou Chakra Charalampos Fragkoulis Source Type: research

How to reduce medication errors in patients over the age of 65?
Expert Opin Pharmacother. 2021 Jun 30:1-5. doi: 10.1080/14656566.2021.1947241. Online ahead of print.NO ABSTRACTPMID:34187264 | DOI:10.1080/14656566.2021.1947241 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Jos é Joaquín Mira Source Type: research

Advances in pharmacotherapy for head and neck cancer
Expert Opin Pharmacother. 2021 Jun 30:1-12. doi: 10.1080/14656566.2021.1948011. Online ahead of print.ABSTRACTIntroduction: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide and is a leading cause for cancer-related mortality. This review attempts to give a comprehensive summary of the recent developments in pharmacotherapeutic options for locally advanced/metastatic HNSCC.Areas covered: In this review, the authors conducted a systematic literature search for published articles on HNSCC in the PubMed database using the keywords 'head and neck squamous cell carcinoma or HNSCC,' 'targe...
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Shikhar Kumar Vanita Noronha Vijay Patil Amit Joshi Nandini Menon Kumar Prabhash Source Type: research

When is it appropriate to treat children with social anxiety, pharmacologically?
Expert Opin Pharmacother. 2021 Jun 30:1-4. doi: 10.1080/14656566.2021.1948015. Online ahead of print.NO ABSTRACTPMID:34187275 | DOI:10.1080/14656566.2021.1948015 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Avigal Snir Danielle M Moskow Stefan G Hofmann Source Type: research

Can cannabinoids still play a role as pain medications?
Expert Opin Pharmacother. 2021 Jun 30:1-3. doi: 10.1080/14656566.2021.1946515. Online ahead of print.NO ABSTRACTPMID:34187250 | DOI:10.1080/14656566.2021.1946515 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Thomas P Pittelkow Neha Pawar Jonathan M Hagedorn Source Type: research

Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer
Expert Opin Pharmacother. 2021 Jun 30:1-9. doi: 10.1080/14656566.2021.1948012. Online ahead of print.ABSTRACTIntroduction:Androgen deprivation therapy (ADT) is currently the backbone treatment of metastatic prostate cancer and is also used in combination with external beam radiotherapy (EBRT). Castration may be achieved either by bilateral orchiectomy or by administration of LHRH agonists or GnRH antagonists.Areas covered: In this article, the authors assess the current and emerging role of GnRH antagonists for the treatment of prostate cancer focusing on oncological results and safety (i.e. cardiovascular risk). In additi...
Source: Expert Opinion on Pharmacotherapy - June 30, 2021 Category: Drugs & Pharmacology Authors: Mohamad Moussa Athanasios Papatsoris Athanasios Dellis Mohamed Abou Chakra Charalampos Fragkoulis Source Type: research